{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:05:04Z","timestamp":1789380304194,"version":"build-2803163510"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"DOI":"10.1007\/s40259-026-00804-x","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:29:04Z","timestamp":1789378144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases"],"prefix":"10.1007","author":[{"given":"Liyan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-3896","authenticated-orcid":false,"given":"Jonas Torbj\u00f6rn","family":"Ungerb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4976-0647","authenticated-orcid":false,"given":"Eric Paul","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-0297","authenticated-orcid":false,"given":"Rasmus O.","family":"Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"804_CR1","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ymthe.2017.03.025","volume":"25","author":"A Biffi","year":"2017","unstructured":"Biffi A. Hematopoietic stem cell gene therapy for storage disease: current and new indications. Mol Ther. 2017;25:1155\u201362. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.025.","journal-title":"Mol Ther"},{"key":"804_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt FM, d\u2019Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4:27. https:\/\/doi.org\/10.1038\/s41572-018-0025-4.","journal-title":"Nat Rev Dis Primers"},{"key":"804_CR3","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.1097\/ms9.0000000000002566","volume":"86","author":"S Bohara","year":"2024","unstructured":"Bohara S, et al. Non-neuronopathic Gaucher disease (Type I) in an elderly female: a case report. Ann Med Surg (Lond). 2024;86:6780\u20133. https:\/\/doi.org\/10.1097\/ms9.0000000000002566.","journal-title":"Ann Med Surg (Lond)"},{"key":"804_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.beem.2014.08.005","volume":"29","author":"GM Pastores","year":"2015","unstructured":"Pastores GM, Hughes DA. Non-neuronopathic lysosomal storage disorders: disease spectrum and treatments. Best Pract Res Clin Endocrinol Metab. 2015;29:173\u201382. https:\/\/doi.org\/10.1016\/j.beem.2014.08.005.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"804_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","volume":"9","author":"R-MN Boustany","year":"2013","unstructured":"Boustany R-MN. Lysosomal storage diseases\u2014the horizon expands. Nat Rev Neurol. 2013;9:583\u201398. https:\/\/doi.org\/10.1038\/nrneurol.2013.163.","journal-title":"Nat Rev Neurol"},{"key":"804_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/156652311794940791","volume":"11","author":"DS Anson","year":"2011","unstructured":"Anson DS, McIntyre C, Byers S. Therapies for neurological disease in the mucopolysaccharidoses. Curr Gene Ther. 2011;11:132\u201343. https:\/\/doi.org\/10.2174\/156652311794940791.","journal-title":"Curr Gene Ther"},{"key":"804_CR7","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2174\/138161208784705504","volume":"14","author":"DJ Begley","year":"2008","unstructured":"Begley DJ, Pontikis CC, Scarpa M. Lysosomal storage diseases and the blood-brain barrier. Curr Pharm Des. 2008;14:1566\u201380. https:\/\/doi.org\/10.2174\/138161208784705504.","journal-title":"Curr Pharm Des"},{"key":"804_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.136080","volume":"760","author":"MP Wasserstein","year":"2021","unstructured":"Wasserstein MP, et al. The future of newborn screening for lysosomal disorders. Neurosci Lett. 2021;760:136080. https:\/\/doi.org\/10.1016\/j.neulet.2021.136080.","journal-title":"Neurosci Lett"},{"key":"804_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2025.104323","volume":"47","author":"YH Chien","year":"2025","unstructured":"Chien YH, Hwu WL. Newborn screening of neurometabolic diseases for early treatment. Brain Dev. 2025;47:104323. https:\/\/doi.org\/10.1016\/j.braindev.2025.104323.","journal-title":"Brain Dev"},{"key":"804_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.21926\/obm.genet.2303194","volume":"07","author":"A Lahr","year":"2023","unstructured":"Lahr A, Williams L, Henderson N, Arnold G, Ortiz D. Overview of newborn screening of lysosomal storage diseases for pediatric care providers. OBM Genetics. 2023;07:194. https:\/\/doi.org\/10.21926\/obm.genet.2303194.","journal-title":"OBM Genetics"},{"key":"804_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2022.100108","volume":"9","author":"J Sheth","year":"2023","unstructured":"Sheth J, Nair A, Jee B. Lysosomal storage disorders: from biology to the clinic with reference to India. Lancet Reg Health Southeast Asia. 2023;9:100108. https:\/\/doi.org\/10.1016\/j.lansea.2022.100108.","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"804_CR12","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1097\/ms9.0000000000002611","volume":"86","author":"C Elendu","year":"2024","unstructured":"Elendu C, et al. Neurological manifestations of lysosomal storage diseases. Ann Med Surg (Lond). 2024;86:6619\u201335. https:\/\/doi.org\/10.1097\/ms9.0000000000002611.","journal-title":"Ann Med Surg (Lond)"},{"key":"804_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3892\/ijmm.2012.1187","volume":"31","author":"G Parenti","year":"2013","unstructured":"Parenti G, Pignata C, Vajro P, Salerno M. New strategies for the treatment of lysosomal storage diseases (Review). Int J Mol Med. 2013;31:11\u201320. https:\/\/doi.org\/10.3892\/ijmm.2012.1187.","journal-title":"Int J Mol Med"},{"key":"804_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.ymthe.2022.11.015","volume":"31","author":"BJ Critchley","year":"2023","unstructured":"Critchley BJ, Gaspar HB, Benedetti S. Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier. Mol Ther. 2023;31:657\u201375. https:\/\/doi.org\/10.1016\/j.ymthe.2022.11.015.","journal-title":"Mol Ther"},{"key":"804_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","volume":"118","author":"M Solomon","year":"2017","unstructured":"Solomon M, Muro S. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev. 2017;118:109\u201334. https:\/\/doi.org\/10.1016\/j.addr.2017.05.004.","journal-title":"Adv Drug Deliv Rev"},{"key":"804_CR16","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1093\/hmg\/ddv457","volume":"25","author":"A Biffi","year":"2016","unstructured":"Biffi A. Gene therapy for lysosomal storage disorders: a good start. Hum Mol Genet. 2016;25:R65-75. https:\/\/doi.org\/10.1093\/hmg\/ddv457.","journal-title":"Hum Mol Genet"},{"key":"804_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1750-1172-6-55","volume":"6","author":"MH de Ru","year":"2011","unstructured":"de Ru MH, et al. Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55. https:\/\/doi.org\/10.1186\/1750-1172-6-55.","journal-title":"Orphanet J Rare Dis"},{"key":"804_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121775","author":"C Fernandez-Pereira","year":"2021","unstructured":"Fernandez-Pereira C, et al. therapeutic approaches in lysosomal storage diseases. Biomolecules. 2021. https:\/\/doi.org\/10.3390\/biom11121775.","journal-title":"Biomolecules"},{"key":"804_CR19","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","volume":"25","author":"M Taylor","year":"2019","unstructured":"Taylor M, et al. Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future. Biol Blood Marrow Transplant. 2019;25:e226\u201346. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.012.","journal-title":"Biol Blood Marrow Transplant"},{"key":"804_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.tips.2021.11.005","volume":"43","author":"R van Gool","year":"2022","unstructured":"van Gool R, et al. Targeting neurological abnormalities in lysosomal storage diseases. Trends Pharmacol Sci. 2022;43:495\u2013509. https:\/\/doi.org\/10.1016\/j.tips.2021.11.005.","journal-title":"Trends Pharmacol Sci"},{"key":"804_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2025.104384","volume":"47","author":"G Consiglieri","year":"2025","unstructured":"Consiglieri G, Tucci F, Bernardo ME. Hematopoietic stem cell gene therapy of neurometabolic lysosomal storage diseases. Brain Dev. 2025;47:104384. https:\/\/doi.org\/10.1016\/j.braindev.2025.104384.","journal-title":"Brain Dev"},{"key":"804_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/19768354.2022.2079719","volume":"26","author":"J Seo","year":"2022","unstructured":"Seo J, Oh DB. Mannose-6-phosphate glycan for lysosomal targeting: various applications from enzyme replacement therapy to lysosome-targeting chimeras. Anim Cells Syst (Seoul). 2022;26:84\u201391. https:\/\/doi.org\/10.1080\/19768354.2022.2079719.","journal-title":"Anim Cells Syst (Seoul)"},{"key":"804_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02052-4","author":"J Muenzer","year":"2021","unstructured":"Muenzer J, et al. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the hunter outcome survey (HOS). Orphanet J Rare Dis. 2021. https:\/\/doi.org\/10.1186\/s13023-021-02052-4.","journal-title":"Orphanet J Rare Dis"},{"key":"804_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","volume":"13","author":"RJ Desnick","year":"2012","unstructured":"Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genom Hum Genet. 2012;13:307\u201335. https:\/\/doi.org\/10.1146\/annurev-genom-090711-163739.","journal-title":"Annu Rev Genom Hum Genet"},{"key":"804_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4161\/auto.5227","volume":"4","author":"C Settembre","year":"2008","unstructured":"Settembre C, Fraldi A, Rubinsztein DC, Ballabio A. Lysosomal storage diseases as disorders of autophagy. Autophagy. 2008;4:113\u20134. https:\/\/doi.org\/10.4161\/auto.5227.","journal-title":"Autophagy"},{"key":"804_CR26","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","volume":"29","author":"R Giugliani","year":"2021","unstructured":"Giugliani R, et al. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: a phase 2 trial in Brazil. Mol Ther. 2021;29:2378\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2021.03.019.","journal-title":"Mol Ther"},{"key":"804_CR27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","volume":"27","author":"T Okuyama","year":"2019","unstructured":"Okuyama T, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial. Mol Ther. 2019;27:456\u201364. https:\/\/doi.org\/10.1016\/j.ymthe.2018.12.005.","journal-title":"Mol Ther"},{"key":"804_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","volume":"29","author":"T Okuyama","year":"2021","unstructured":"Okuyama T, et al. A phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol Ther. 2021;29:671\u20139. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.039.","journal-title":"Mol Ther"},{"key":"804_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70612","author":"K Nakamura","year":"2026","unstructured":"Nakamura K, et al. Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II. Br J Clin Pharmacol. 2026. https:\/\/doi.org\/10.1002\/bcp.70612.","journal-title":"Br J Clin Pharmacol"},{"key":"804_CR30","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s11011-021-00893-3","volume":"37","author":"Y Sato","year":"2022","unstructured":"Sato Y, et al. Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid. Metab Brain Dis. 2022;37:1745\u201356. https:\/\/doi.org\/10.1007\/s11011-021-00893-3.","journal-title":"Metab Brain Dis"},{"key":"804_CR31","doi-asserted-by":"publisher","DOI":"10.1088\/2399-1984\/aadd34","volume":"2","author":"M Goldsmith","year":"2018","unstructured":"Goldsmith M, Abramovitz L, Braunstein H, Horowitz M, Peer D. Quantitative analysis of recombinant glucocerebrosidase brain delivery via lipid nanoparticles. Nano Futures. 2018;2:045003. https:\/\/doi.org\/10.1088\/2399-1984\/aadd34.","journal-title":"Nano Futures"},{"key":"804_CR32","doi-asserted-by":"publisher","first-page":"eaax7462","DOI":"10.1126\/sciadv.aax7462","volume":"5","author":"A Del Grosso","year":"2019","unstructured":"Del Grosso A, et al. Brain-targeted enzyme-loaded nanoparticles: a breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease. Sci Adv. 2019;5:eaax7462. https:\/\/doi.org\/10.1126\/sciadv.aax7462.","journal-title":"Sci Adv"},{"key":"804_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20082014","author":"L Rigon","year":"2019","unstructured":"Rigon L, et al. Targeting brain disease in MPSII: preclinical evaluation of IDS-loaded PLGA nanoparticles. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20082014.","journal-title":"Int J Mol Sci"},{"key":"804_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2007.05.022","volume":"122","author":"G Tosi","year":"2007","unstructured":"Tosi G, et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J Control Release. 2007;122:1\u20139. https:\/\/doi.org\/10.1016\/j.jconrel.2007.05.022.","journal-title":"J Control Release"},{"key":"804_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2217\/nnm.11.11","volume":"6","author":"G Tosi","year":"2011","unstructured":"Tosi G, et al. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine (Lond). 2011;6:423\u201336. https:\/\/doi.org\/10.2217\/nnm.11.11.","journal-title":"Nanomedicine (Lond)"},{"key":"804_CR36","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.1038\/s41467-025-60959-z","volume":"16","author":"JM Johansson","year":"2025","unstructured":"Johansson JM, et al. Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol. Nat Commun. 2025;16:5354. https:\/\/doi.org\/10.1038\/s41467-025-60959-z.","journal-title":"Nat Commun"},{"key":"804_CR37","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1016\/j.ymgme.2018.12.396","volume":"126","author":"F Wijburg","year":"2019","unstructured":"Wijburg F, et al. Design, baseline characteristics, and 18\u201324 months follow-up from the MPS IIIA natural history study. Mol Genet Metab. 2019;126:S153. https:\/\/doi.org\/10.1016\/j.ymgme.2018.12.396.","journal-title":"Mol Genet Metab"},{"key":"804_CR38","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/s41436-019-0522-1","volume":"21","author":"JB Eisengart","year":"2019","unstructured":"Eisengart JB, et al. Intrathecal enzyme replacement for Hurler syndrome: biomarker association with neurocognitive outcomes. Genet Med. 2019;21:2552\u201360. https:\/\/doi.org\/10.1038\/s41436-019-0522-1.","journal-title":"Genet Med"},{"key":"804_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa2508681","volume":"394","author":"J Muenzer","year":"2025","unstructured":"Muenzer J, et al. An intravenous brain-penetrant enzyme therapy for mucopolysaccharidosis II. N Engl J Med. 2025;394:39\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2508681.","journal-title":"N Engl J Med"},{"key":"804_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/TACG.S57682","volume":"8","author":"DP Rastall","year":"2015","unstructured":"Rastall DP, Amalfitano A. Recent advances in gene therapy for lysosomal storage disorders. Appl Clin Genet. 2015;8:157\u201369. https:\/\/doi.org\/10.2147\/TACG.S57682.","journal-title":"Appl Clin Genet"},{"key":"804_CR41","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2510935","volume":"394","author":"J Lewis Connor","year":"2026","unstructured":"Lewis Connor J, et al. AAV9 gene therapy in Type II GM1 gangliosidosis \u2014 a phase 1\u20132 trial. N Eng J Med. 2026;394:1184\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2510935.","journal-title":"N Eng J Med"},{"key":"804_CR42","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2012.101","volume":"20","author":"SJ Gray","year":"2013","unstructured":"Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 2013;20:450\u20139. https:\/\/doi.org\/10.1038\/gt.2012.101.","journal-title":"Gene Ther"},{"key":"804_CR43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","volume":"23","author":"K Meyer","year":"2015","unstructured":"Meyer K, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther. 2015;23:477\u201387. https:\/\/doi.org\/10.1038\/mt.2014.210.","journal-title":"Mol Ther"},{"key":"804_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.crneur.2023.100086","volume":"4","author":"LJ Campos","year":"2023","unstructured":"Campos LJ, et al. Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system. Curr Res Neurobiol. 2023;4:100086. https:\/\/doi.org\/10.1016\/j.crneur.2023.100086.","journal-title":"Curr Res Neurobiol"},{"key":"804_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","volume":"25","author":"D Goertsen","year":"2022","unstructured":"Goertsen D, et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat Neurosci. 2022;25:106\u201315. https:\/\/doi.org\/10.1038\/s41593-021-00969-4.","journal-title":"Nat Neurosci"},{"key":"804_CR46","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan KY, et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017;20:1172\u20139. https:\/\/doi.org\/10.1038\/nn.4593.","journal-title":"Nat Neurosci"},{"key":"804_CR47","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd.2015.21","volume":"15","author":"WA Banks","year":"2016","unstructured":"Banks WA. From blood\u2013brain barrier to blood\u2013brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15:275\u201392. https:\/\/doi.org\/10.1038\/nrd.2015.21.","journal-title":"Nat Rev Drug Discov"},{"key":"804_CR48","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","volume":"27","author":"WA Liguore","year":"2019","unstructured":"Liguore WA, et al. AAV-PHP.B administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice. Mol Ther. 2019;27:2018\u201337. https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.017.","journal-title":"Mol Ther"},{"key":"804_CR49","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41434-024-00466-w","volume":"31","author":"M Bunuales","year":"2024","unstructured":"Bunuales M, et al. Characterization of brain transduction capability of a BBB-penetrant AAV vector in mice, rats and macaques reveals differences in expression profiles. Gene Ther. 2024;31:455\u201366. https:\/\/doi.org\/10.1038\/s41434-024-00466-w.","journal-title":"Gene Ther"},{"key":"804_CR50","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/hum.2016.087","volume":"27","author":"M Hocquemiller","year":"2016","unstructured":"Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N. Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther. 2016;27:478\u201396. https:\/\/doi.org\/10.1089\/hum.2016.087.","journal-title":"Hum Gene Ther"},{"key":"804_CR51","doi-asserted-by":"publisher","first-page":"1064924","DOI":"10.3389\/fgene.2023.1064924","volume":"14","author":"J Kido","year":"2023","unstructured":"Kido J, Sugawara K, Nakamura K. Gene therapy for lysosomal storage diseases: current clinical trial prospects. Front Genet. 2023;14:1064924. https:\/\/doi.org\/10.3389\/fgene.2023.1064924.","journal-title":"Front Genet"},{"key":"804_CR52","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2601608","volume":"394","author":"C Ahrens-Nicklas Rebecca","year":"2026","unstructured":"Ahrens-Nicklas Rebecca C, et al. Neuroepithelial tumor with aav integration after intracisternal magna vector delivery. N Engl J Med. 2026;394:2126\u201333. https:\/\/doi.org\/10.1056\/NEJMoa2601608.","journal-title":"N Engl J Med"},{"key":"804_CR53","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1016\/j.ymthe.2026.04.016","volume":"34","author":"RY Wang","year":"2026","unstructured":"Wang RY, et al. First-in-human intracisternal dosing of RGX-111 in severe MPS I is well tolerated and generates sustained neurodevelopment without HSCT. Mol Ther. 2026;34:3217\u201323. https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.016.","journal-title":"Mol Ther"},{"key":"804_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-0-387-78580-6_1","volume":"144","author":"S Giralt","year":"2009","unstructured":"Giralt S, Bishop MR. Principles and overview of allogeneic hematopoietic stem cell transplantation. Cancer Treat Res. 2009;144:1\u201321. https:\/\/doi.org\/10.1007\/978-0-387-78580-6_1.","journal-title":"Cancer Treat Res"},{"key":"804_CR55","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1073\/pnas.0306431101","volume":"101","author":"M Asheuer","year":"2004","unstructured":"Asheuer M, et al. Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc Natl Acad Sci U S A. 2004;101:3557\u201362. https:\/\/doi.org\/10.1073\/pnas.0306431101.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"804_CR56","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1182\/bloodadvances.2023010409","volume":"7","author":"AM Loeb","year":"2023","unstructured":"Loeb AM, Pattwell SS, Meshinchi S, Bedalov A, Loeb KR. Donor bone marrow-derived macrophage engraftment into the central nervous system of patients following allogeneic transplantation. Blood Adv. 2023;7:5851\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023010409.","journal-title":"Blood Adv"},{"key":"804_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24246","author":"M Poe","year":"2014","unstructured":"Poe M, Chagnon S, Escolar M. Early treatment is associated with improved cognition in Hurler syndrome. Ann Neurol. 2014. https:\/\/doi.org\/10.1002\/ana.24246.","journal-title":"Ann Neurol"},{"key":"804_CR58","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.celrep.2017.07.004","volume":"20","author":"P R\u00e9u","year":"2017","unstructured":"R\u00e9u P, et al. The lifespan and turnover of microglia in the human brain. Cell Rep. 2017;20:779\u201384. https:\/\/doi.org\/10.1016\/j.celrep.2017.07.004.","journal-title":"Cell Rep"},{"key":"804_CR59","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ni.3423","volume":"17","author":"T Goldmann","year":"2016","unstructured":"Goldmann T, et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat Immunol. 2016;17:797\u2013805. https:\/\/doi.org\/10.1038\/ni.3423.","journal-title":"Nat Immunol"},{"key":"804_CR60","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/nn2014","volume":"10","author":"B Ajami","year":"2007","unstructured":"Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10:1538\u201343. https:\/\/doi.org\/10.1038\/nn2014.","journal-title":"Nat Neurosci"},{"key":"804_CR61","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164\u201372. https:\/\/doi.org\/10.1182\/blood-2014-11-608075.","journal-title":"Blood"},{"key":"804_CR62","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/096368979500400409","volume":"4","author":"W Krivit","year":"1995","unstructured":"Krivit W, Sung JH, Shapiro EG, Lockman LA. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. 1995;4:385\u201392. https:\/\/doi.org\/10.1177\/096368979500400409.","journal-title":"Cell Transplant"},{"key":"804_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.895511","volume":"16","author":"P de Vasconcelos","year":"2022","unstructured":"de Vasconcelos P, Lacerda JF. Hematopoietic Stem Cell Transplantation for Neurological Disorders: A Focus on Inborn Errors of Metabolism. Front Cell Neurosci. 2022;16:895511. https:\/\/doi.org\/10.3389\/fncel.2022.895511.","journal-title":"Front Cell Neurosci"},{"key":"804_CR64","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1073\/pnas.1205858109","volume":"109","author":"A Capotondo","year":"2012","unstructured":"Capotondo A, et al. Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation. Proc Natl Acad Sci U S A. 2012;109:15018\u201323. https:\/\/doi.org\/10.1073\/pnas.1205858109.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"804_CR65","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1056\/NEJMp048084","volume":"350","author":"J Muenzer","year":"2004","unstructured":"Muenzer J, Fisher A. Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med. 2004;350:1932\u20134. https:\/\/doi.org\/10.1056\/NEJMp048084.","journal-title":"N Engl J Med"},{"key":"804_CR66","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1651-2227.1990.tb11535.x","volume":"79","author":"A Erikson","year":"1990","unstructured":"Erikson A, et al. Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type. Acta Paediatr Scand. 1990;79:680\u20135. https:\/\/doi.org\/10.1111\/j.1651-2227.1990.tb11535.x.","journal-title":"Acta Paediatr Scand"},{"key":"804_CR67","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1056\/NEJM198407123110203","volume":"311","author":"JM Rappeport","year":"1984","unstructured":"Rappeport JM, Ginns EI. Bone-marrow transplantation in severe Gaucher\u2019s disease. N Engl J Med. 1984;311:84\u20138. https:\/\/doi.org\/10.1056\/NEJM198407123110203.","journal-title":"N Engl J Med"},{"key":"804_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.135841","volume":"752","author":"AM Bradbury","year":"2021","unstructured":"Bradbury AM, Bongarzone ER, Sands MS. Krabbe disease: New hope for an old disease. Neurosci Lett. 2021;752:135841. https:\/\/doi.org\/10.1016\/j.neulet.2021.135841.","journal-title":"Neurosci Lett"},{"key":"804_CR69","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296\u2013307. https:\/\/doi.org\/10.1182\/blood-2011-06-364265.","journal-title":"Blood"},{"key":"804_CR70","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/bmt.2010.5","volume":"45","author":"S Pallua","year":"2010","unstructured":"Pallua S, et al. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation. Bone Marrow Transplant. 2010;45:1534\u20139. https:\/\/doi.org\/10.1038\/bmt.2010.5.","journal-title":"Bone Marrow Transplant"},{"key":"804_CR71","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","volume":"385","author":"B Gentner","year":"2021","unstructured":"Gentner B, et al. Hematopoietic stem- and progenitor-cell gene therapy for Hurler syndrome. N Engl J Med. 2021;385:1929\u201340. https:\/\/doi.org\/10.1056\/NEJMoa2106596.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"804_CR72","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.5414\/cpp47128","volume":"47","author":"C Sevin","year":"2009","unstructured":"Sevin C, Cartier-Lacave N, Aubourg P. Gene therapy in metachromatic leukodystrophy. Int J Clin Pharmacol Ther. 2009;47(Suppl 1):S128-131. https:\/\/doi.org\/10.5414\/cpp47128.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"804_CR73","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi A, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158. https:\/\/doi.org\/10.1126\/science.1233158.","journal-title":"Science"},{"key":"804_CR74","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","volume":"399","author":"F Fumagalli","year":"2022","unstructured":"Fumagalli F, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet. 2022;399:372\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(21)02017-1.","journal-title":"Lancet"},{"key":"804_CR75","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","volume":"388","author":"M Sessa","year":"2016","unstructured":"Sessa M, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial. Lancet. 2016;388:476\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(16)30374-9.","journal-title":"Lancet"},{"key":"804_CR76","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-017-0052-4","volume":"40","author":"R Penati","year":"2017","unstructured":"Penati R, Fumagalli F, Calbi V, Bernardo ME, Aiuti A. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. J Inherit Metab Dis. 2017;40:543\u201354. https:\/\/doi.org\/10.1007\/s10545-017-0052-4.","journal-title":"J Inherit Metab Dis"},{"key":"804_CR77","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40348-020-00103-7","volume":"7","author":"J Beschle","year":"2020","unstructured":"Beschle J, et al. Early clinical course after hematopoietic stem cell transplantation in children with juvenile metachromatic leukodystrophy. Mol Cell Pediatr. 2020;7:12. https:\/\/doi.org\/10.1186\/s40348-020-00103-7.","journal-title":"Mol Cell Pediatr"},{"key":"804_CR78","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1590\/0004-282X20160155","volume":"74","author":"JA Saute","year":"2016","unstructured":"Saute JA, et al. Neurological outcomes after hematopoietic stem cell transplantation for cerebral X-linked adrenoleukodystrophy, late onset metachromatic leukodystrophy and Hurler syndrome. Arq Neuropsiquiatr. 2016;74:953\u201366. https:\/\/doi.org\/10.1590\/0004-282X20160155.","journal-title":"Arq Neuropsiquiatr"},{"key":"804_CR79","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa2405727","volume":"392","author":"F Fumagalli","year":"2025","unstructured":"Fumagalli F, et al. Long-term effects of atidarsagene autotemcel for metachromatic leukodystrophy. N Engl J Med. 2025;392:1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2405727.","journal-title":"N Engl J Med"},{"key":"804_CR80","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","volume":"539","author":"DP Dever","year":"2016","unstructured":"Dever DP, et al. CRISPR\/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539:384\u20139. https:\/\/doi.org\/10.1038\/nature20134.","journal-title":"Nature"},{"key":"804_CR81","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9.","journal-title":"Nat Rev Drug Discov"},{"key":"804_CR82","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","volume":"391","author":"CN Duncan","year":"2024","unstructured":"Duncan CN, et al. Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2024;391:1287\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa2405541.","journal-title":"N Engl J Med"},{"key":"804_CR83","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.hoc.2017.06.004","volume":"31","author":"A Biffi","year":"2017","unstructured":"Biffi A. Hematopoietic gene therapies for metabolic and neurologic diseases. Hematol Oncol Clin North Am. 2017;31:869\u201381. https:\/\/doi.org\/10.1016\/j.hoc.2017.06.004.","journal-title":"Hematol Oncol Clin North Am"},{"key":"804_CR84","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1038\/s41467-024-49908-4","volume":"15","author":"P Colella","year":"2024","unstructured":"Colella P, et al. CNS-wide repopulation by hematopoietic-derived microglia-like cells corrects progranulin deficiency in mice. Nat Commun. 2024;15:5654. https:\/\/doi.org\/10.1038\/s41467-024-49908-4.","journal-title":"Nat Commun"},{"key":"804_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.10.050","author":"SI Lombroso","year":"2025","unstructured":"Lombroso SI, et al. Microglia replacement by peripheral delivery of CSF1R inhibitor-resistant hematopoietic cells. Mol Ther. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.10.050.","journal-title":"Mol Ther"},{"key":"804_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.624988","volume":"8","author":"C Sevin","year":"2021","unstructured":"Sevin C, Deiva K. Clinical trials for gene therapy in lysosomal diseases with CNS involvement. Front Mol Biosci. 2021;8:624988. https:\/\/doi.org\/10.3389\/fmolb.2021.624988.","journal-title":"Front Mol Biosci"},{"key":"804_CR87","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","volume":"13","author":"F Tucci","year":"2022","unstructured":"Tucci F, Galimberti S, Naldini L, Valsecchi MG, Aiuti A. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders. Nat Commun. 2022;13:1315. https:\/\/doi.org\/10.1038\/s41467-022-28762-2.","journal-title":"Nat Commun"},{"key":"804_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e03635","volume":"6","author":"MA Puentes-Tellez","year":"2020","unstructured":"Puentes-Tellez MA, et al. A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia. Heliyon. 2020;6:e03635. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e03635.","journal-title":"Heliyon"},{"key":"804_CR89","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imj.15100","volume":"50","author":"H Peters","year":"2020","unstructured":"Peters H, Ellaway C, Nicholls K, Reardon K, Szer J. Treatable lysosomal storage diseases in the advent of disease-specific therapy. Intern Med J. 2020;50:5\u201327. https:\/\/doi.org\/10.1111\/imj.15100.","journal-title":"Intern Med J"},{"key":"804_CR90","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/biom11121775","volume":"11","author":"C Fern\u00e1ndez-Pereira","year":"2021","unstructured":"Fern\u00e1ndez-Pereira C, et al. Therapeutic approaches in lysosomal storage diseases. Biomolecules. 2021;11:1775. https:\/\/doi.org\/10.3390\/biom11121775.","journal-title":"Biomolecules"},{"key":"804_CR91","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40259-024-00644-7","volume":"38","author":"S Chen","year":"2024","unstructured":"Chen S, et al. Splice-modulating antisense oligonucleotides as therapeutics for inherited metabolic diseases. BioDrugs. 2024;38:177\u2013203. https:\/\/doi.org\/10.1007\/s40259-024-00644-7.","journal-title":"BioDrugs"},{"key":"804_CR92","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","volume":"97","author":"FM Platt","year":"2008","unstructured":"Platt FM, Jeyakumar M. Substrate reduction therapy. Acta Paediatr. 2008;97:88\u201393. https:\/\/doi.org\/10.1111\/j.1651-2227.2008.00656.x.","journal-title":"Acta Paediatr"},{"key":"804_CR93","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/s0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox T, et al. Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355:1481\u20135. https:\/\/doi.org\/10.1016\/s0140-6736(00)02161-9.","journal-title":"Lancet"},{"key":"804_CR94","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/s1474-4422(07)70194-1","volume":"6","author":"MC Patterson","year":"2007","unstructured":"Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6:765\u201372. https:\/\/doi.org\/10.1016\/s1474-4422(07)70194-1.","journal-title":"Lancet Neurol"},{"key":"804_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030616","author":"C Para","year":"2020","unstructured":"Para C, Bose P, Pshezhetsky AV. Neuropathophysiology of lysosomal storage diseases: synaptic dysfunction as a starting point for disease progression. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9030616.","journal-title":"J Clin Med"},{"key":"804_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810573","author":"KM Stepien","year":"2022","unstructured":"Stepien KM, et al. Secondary Mitochondrial Dysfunction as a Cause of Neurodegenerative Dysfunction in Lysosomal Storage Diseases and an Overview of Potential Therapies. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231810573.","journal-title":"Int J Mol Sci"},{"key":"804_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.70034","volume":"48","author":"R Schiffmann","year":"2025","unstructured":"Schiffmann R. Role of biomarkers in diagnosing disease, assessing the severity and progression of disease, and evaluating the efficacy of therapies. J Inherit Metab Dis. 2025;48:e70034. https:\/\/doi.org\/10.1002\/jimd.70034.","journal-title":"J Inherit Metab Dis"},{"key":"804_CR98","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.gim.2024.101242","volume":"27","author":"AR Stiles","year":"2025","unstructured":"Stiles AR, Donti TR, Hall PL, Wilcox WR. Biomarker testing for lysosomal diseases: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2025;27:101242. https:\/\/doi.org\/10.1016\/j.gim.2024.101242.","journal-title":"Genet Med"},{"key":"804_CR99","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajmg.a.20117","volume":"120A","author":"C Mignot","year":"2003","unstructured":"Mignot C, et al. Perinatal-lethal Gaucher disease. Am J Med Genet A. 2003;120A:338\u201344. https:\/\/doi.org\/10.1002\/ajmg.a.20117.","journal-title":"Am J Med Genet A"},{"key":"804_CR100","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"741\u2013748","author":"SM Rombach","year":"1802","unstructured":"Rombach SM, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 1802;741\u2013748:2010. https:\/\/doi.org\/10.1016\/j.bbadis.2010.05.003.","journal-title":"Biochim Biophys Acta"},{"key":"804_CR101","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/dmcn.13740","volume":"60","author":"BJ Ebbink","year":"2018","unstructured":"Ebbink BJ, et al. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol. 2018;60:579\u201386. https:\/\/doi.org\/10.1111\/dmcn.13740.","journal-title":"Dev Med Child Neurol"},{"issue":"Suppl 1","key":"804_CR102","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.pedneo.2022.10.001","volume":"64","author":"M Penon-Portmann","year":"2023","unstructured":"Penon-Portmann M, Blair DR, Harmatz P. Current and new therapies for mucopolysaccharidoses. Pediatr Neonatol. 2023;64(Suppl 1):S10\u20137. https:\/\/doi.org\/10.1016\/j.pedneo.2022.10.001.","journal-title":"Pediatr Neonatol"},{"key":"804_CR103","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1523\/JNEUROSCI.0217-13.2013","volume":"33","author":"L Cantuti Castelvetri","year":"2013","unstructured":"Cantuti Castelvetri L, et al. The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3beta and deregulation of molecular motors. J Neurosci. 2013;33:10048\u201356. https:\/\/doi.org\/10.1523\/JNEUROSCI.0217-13.2013.","journal-title":"J Neurosci"},{"key":"804_CR104","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.21931\/rb\/2021.06.03.32","volume":"3","author":"NTS Alvarez","year":"2021","unstructured":"Alvarez NTS, Bautista-Ni\u00f1o PK, Trejos-Su\u00e1rez J, Serrano NC. Metachromatic leukodystrophy: diagnosis and treatment challenges. Bionatura. 2021;3:2083\u201390. https:\/\/doi.org\/10.21931\/rb\/2021.06.03.32.","journal-title":"Bionatura"},{"key":"804_CR105","doi-asserted-by":"publisher","first-page":"10954","DOI":"10.1073\/pnas.97.20.10954","volume":"97","author":"R Wada","year":"2000","unstructured":"Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A. 2000;97:10954\u20139. https:\/\/doi.org\/10.1073\/pnas.97.20.10954.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"804_CR106","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1046\/j.1471-4159.1996.67020677.x","volume":"67","author":"SC Lane","year":"1996","unstructured":"Lane SC, Jolly RD, Schmechel DE, Alroy J, Boustany RM. Apoptosis as the mechanism of neurodegeneration in Batten\u2019s disease. J Neurochem. 1996;67:677\u201383. https:\/\/doi.org\/10.1046\/j.1471-4159.1996.67020677.x.","journal-title":"J Neurochem"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00804-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00804-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00804-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:29:06Z","timestamp":1789378146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00804-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":106,"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00804-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"30 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.O.B. holds equity in Kamau Therapeutics and UNIKUM Therapeutics and is a cofounder of UNIKUM Therapeutics. Neither company was involved in the present study. R.O.B. is an inventor on patents and patent applications related to CRISPR\/Cas and cellular therapies. R.O.B. reports research funding from Novo Nordisk. L.Q., J.T.U., and E.P.B. are employees of Novo Nordisk.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.Q. took the lead in writing the manuscript with assistance from J.T.U., E.P.B., and R.O.B. L.Q. drafted the figures with input from J.T.U., E.P.B., and R.O.B. All authors reviewed, edited, and approved the final manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}